Mangeng Cheng

7.8k total citations · 3 hit papers
46 papers, 5.8k citations indexed

About

Mangeng Cheng is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mangeng Cheng has authored 46 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Molecular Biology, 18 papers in Oncology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mangeng Cheng's work include Lung Cancer Treatments and Mutations (13 papers), Cancer therapeutics and mechanisms (11 papers) and Neuroblastoma Research and Treatments (9 papers). Mangeng Cheng is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Cancer therapeutics and mechanisms (11 papers) and Neuroblastoma Research and Treatments (9 papers). Mangeng Cheng collaborates with scholars based in United States, Italy and Denmark. Mangeng Cheng's co-authors include Charles J. Sherr, Martine F. Roussel, J. Alan Diehl, Melanie H. Cobb, Veronika Sexl, Bruce Ruggeri, David J. Robbins, Mariusz A. Wasik, Michał Marzec and Ami Goradia and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Mangeng Cheng

46 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization

1998 1.8k citations J. Alan Diehl, Mangeng Cheng et al. Genes & Development profile →
The p21Cip1 and p27Kip1 CDK `inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts

1999 952 citations Mangeng Cheng profile →
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

2008 597 citations Michał Marzec, Mangeng Cheng et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mangeng Cheng United States	28	3.9k	2.9k	749	721	693	46	5.8k
Viví Ann Flørenes Norway	42	3.5k 0.9×	2.2k 0.8×	620 0.8×	603 0.8×	780 1.1×	108	5.4k
Martin van der Valk Netherlands	33	4.0k 1.0×	3.6k 1.2×	570 0.8×	570 0.8×	444 0.6×	45	6.9k
Rosa Marina Melillo Italy	47	3.6k 0.9×	2.6k 0.9×	985 1.3×	427 0.6×	501 0.7×	100	6.8k
Hiroaki Kiyokawa United States	47	5.5k 1.4×	3.5k 1.2×	493 0.7×	1.2k 1.7×	599 0.9×	117	7.8k
Jonathan A. Pachter United States	32	2.4k 0.6×	1.7k 0.6×	741 1.0×	612 0.8×	507 0.7×	137	4.4k
Hui‐Wen Lo United States	48	4.5k 1.1×	3.3k 1.1×	709 0.9×	421 0.6×	1.5k 2.2×	113	7.7k
Stefano Pepe Italy	45	2.6k 0.7×	2.5k 0.9×	440 0.6×	302 0.4×	1.1k 1.5×	130	5.3k
Mohamed Rahmani United States	47	3.9k 1.0×	1.4k 0.5×	586 0.8×	593 0.8×	282 0.4×	95	5.7k
Laura Soucek Spain	32	3.7k 0.9×	1.7k 0.6×	855 1.1×	256 0.4×	305 0.4×	54	5.0k
Pablo Rodriguez‐Viciana United States	24	5.2k 1.3×	1.5k 0.5×	731 1.0×	1.1k 1.6×	259 0.4×	31	6.3k

Countries citing papers authored by Mangeng Cheng

Since Specialization

Citations

This map shows the geographic impact of Mangeng Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mangeng Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mangeng Cheng more than expected).

Fields of papers citing papers by Mangeng Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mangeng Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mangeng Cheng. The network helps show where Mangeng Cheng may publish in the future.

Co-authorship network of co-authors of Mangeng Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Mangeng Cheng. A scholar is included among the top collaborators of Mangeng Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mangeng Cheng. Mangeng Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moure, Casey J., Brandon Vara, Mangeng Cheng, et al.. (2024). Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor. Molecular Cancer Therapeutics. 23(8). 1095–1108. 5 indexed citations

Xiang, Handan, Carlo P. Ramil, Josephine Hai, et al.. (2020). Cancer-Associated Fibroblasts Promote Immunosuppression by Inducing ROS-Generating Monocytic MDSCs in Lung Squamous Cell Carcinoma. Cancer Immunology Research. 8(4). 436–450. 190 indexed citations

Boi, Michela, Maria Chiara Todaro, Valentina Vurchio, et al.. (2016). Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. Oncotarget. 7(48). 79637–79653. 19 indexed citations

Mesaros, Eugen F., Thelma S. Angeles, Mark S. Albom, et al.. (2015). Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinase. Bioorganic & Medicinal Chemistry Letters. 25(5). 1047–1052. 14 indexed citations

Voena, Claudia, Filomena Di Giacomo, Elena Panizza, et al.. (2013). The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. Oncogenesis. 2(4). e43–e43. 26 indexed citations

Yao, Sheng, Mangeng Cheng, Qian Zhang, et al.. (2013). Anaplastic Lymphoma Kinase Is Required for Neurogenesis in the Developing Central Nervous System of Zebrafish. PLoS ONE. 8(5). e63757–e63757. 56 indexed citations

Cheng, Mangeng, Matthew R. Quail, Diane E. Gingrich, et al.. (2011). CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers. Molecular Cancer Therapeutics. 11(3). 670–679. 59 indexed citations

Zificsak, Craig A., Jay Theroff, Lisa D. Aimone, et al.. (2011). Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(13). 3877–3880. 18 indexed citations

Tripathy, Rabindranath, Robert J. McHugh, Arup K. Ghose, et al.. (2011). Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: Control of selectivity by a benzyloxy group. Bioorganic & Medicinal Chemistry Letters. 21(24). 7261–7264. 27 indexed citations

10.

Mesaros, Eugen F., Jason P. Burke, Jonathan D. Parrish, et al.. (2010). Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models. Bioorganic & Medicinal Chemistry Letters. 21(1). 463–466. 27 indexed citations

11.

Cheng, Mangeng & Gregory R. Ott. (2010). Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma. Anti-Cancer Agents in Medicinal Chemistry. 10(3). 236–249. 30 indexed citations

12.

Marzec, Michał, Won Fen Wong, Yun Yang, et al.. (2010). Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA. Oncogene. 30(11). 1372–1378. 31 indexed citations

13.

Passoni, Lorena, Luca Longo, Paola Collini, et al.. (2009). Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients. Cancer Research. 69(18). 7338–7346. 129 indexed citations

14.

Piva, Roberto, Elisa Pellegrino, Michela Mattioli, et al.. (2006). Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes. Journal of Clinical Investigation. 116(12). 3171–3182. 133 indexed citations

15.

Cheng, Mangeng, Demin Wang, & Martine F. Roussel. (1999). Expression of c-Myc in Response to Colony-stimulating Factor-1 Requires Mitogen-activated Protein Kinase Kinase-1. Journal of Biological Chemistry. 274(10). 6553–6558. 49 indexed citations

16.

Diehl, J. Alan, Mangeng Cheng, Martine F. Roussel, & Charles J. Sherr. (1998). Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes & Development. 12(22). 3499–3511. 1805 indexed citations breakdown →

17.

Davis, J. Nathan, Charles O. Rock, Mangeng Cheng, et al.. (1997). Complementation of Growth Factor Receptor-Dependent Mitogenic Signaling by a Truncated Type I Phosphatidylinositol 4-Phosphate 5-Kinase. Molecular and Cellular Biology. 17(12). 7398–7406. 35 indexed citations

18.

Cobb, Melanie H., Shuichan Xu, Mangeng Cheng, et al.. (1996). Structural Analysis of the MAP Kinase ERK2 and Studies of MAP Kinase Regulatory Pathways. Advances in pharmacology. 36. 49–65. 24 indexed citations

19.

Cheng, Mangeng, et al.. (1996). Characterization of a Protein Kinase that Phosphorylates Serine 189 of the Mitogen-activated Protein Kinase Homolog ERK3. Journal of Biological Chemistry. 271(20). 12057–12062. 40 indexed citations

20.

Robbins, David J., et al.. (1994). Map Kinases Erk1 And Erk2: Pleiotropic Enzymes In A Ubiquitous Signaling Network. Advances in cancer research. 63. 93–116. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact